Carisma Therapeutics, Inc.
CARMOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$4185
P/E Ratio—
52W High$1.27
52W Low$0.0001
Carisma Therapeutics, Inc. (CARM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CARM · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 12, 2025EPS Actual
$1.07
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 12, 2025
After Market Close
✓ 1-Quarter EPS Beat Streak
CARM reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 29, 2026 | -$0.15 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | May 28, 2026 | -$0.15 | — | — | — | $0.00B | — |
| — Q4 FY2025 | Nov 12, 2025 | — | $1.07 | — | — | — | — |
| — Q3 FY2025 | Aug 7, 2025 | -$0.12 | -$0.12 | +0.0% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.12 | -$0.22 | -83.3% | $0.00B | $0.00B | +98.9% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.16 | -$0.42 | -162.5% | $0.00B | $0.00B | +48.0% |
| — Q4 FY2024 | Nov 7, 2024 | -$0.31 | -$0.31 | +0.0% | $0.00B | $0.01B | -37.6% |
| ▲ Q3 FY2024 | Aug 8, 2024 | -$0.36 | -$0.27 | +25.0% | $0.01B | $0.00B | +134.6% |
Q2 FY2026
May 29, 2026
EPS Actual
—
EPS Est.
-$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 28, 2026
EPS Actual
—
EPS Est.
-$0.15
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 12, 2025
EPS Actual
$1.07
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 7, 2025
EPS Actual
-$0.12
EPS Est.
-$0.12
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.22
EPS Est.
-$0.12
EPS Surpr.
-83.3%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.42
EPS Est.
-$0.16
EPS Surpr.
-162.5%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024
EPS Actual
-$0.31
EPS Est.
-$0.31
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2024
Aug 8, 2024Beat
EPS Actual
-$0.27
EPS Est.
-$0.36
EPS Surpr.
+25.0%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q3 FY2028 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q2 FY2028 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q1 FY2028 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q4 FY2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q3 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2025 | Nov 12, 2025 | — | $0.05 | $0.05 | -6.25% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +0.0% | $0.31 | $0.28 | -9.90% |
| ▼ Q2 FY2025 | May 13, 2025 | -83.3% | $0.19 | $0.19 | -3.73% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -162.5% | $0.33 | $0.31 | -6.06% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +0.0% | $1.11 | $1.03 | -7.21% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +25.0% | $0.80 | $0.90 | +12.62% |
| ▼ Q2 FY2024 | May 9, 2024 | -24.3% | $1.55 | $1.51 | -2.58% |
| ▲ Q1 FY2024 | Mar 26, 2024 | +5.5% | $2.52 | $2.30 | -8.73% |
Q4 FY2025-6.25%
Report Date
Nov 12, 2025
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Q3 FY2025-9.90%
Report Date
Aug 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.31
Price After
$0.28
Q2 FY2025-3.73%
Report Date
May 13, 2025
EPS Beat/Miss
-83.3%
Price Before
$0.19
Price After
$0.19
Q1 FY2025-6.06%
Report Date
Mar 31, 2025
EPS Beat/Miss
-162.5%
Price Before
$0.33
Price After
$0.31
Q4 FY2024-7.21%
Report Date
Nov 7, 2024
EPS Beat/Miss
+0.0%
Price Before
$1.11
Price After
$1.03
Q3 FY2024+12.62%
Report Date
Aug 8, 2024
EPS Beat/Miss
+25.0%
Price Before
$0.80
Price After
$0.90
Q2 FY2024-2.58%
Report Date
May 9, 2024
EPS Beat/Miss
-24.3%
Price Before
$1.55
Price After
$1.51
Q1 FY2024-8.73%
Report Date
Mar 26, 2024
EPS Beat/Miss
+5.5%
Price Before
$2.52
Price After
$2.30
Avg Beat Reaction-3.31%
Avg Miss Reaction-4.12%
Beat Rate4 / 8 quarters
Largest Move+12.62% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CARM ends December
Carisma Therapeutics, Inc. (CARM) most recently reported earnings on November 12, 2025 for Q4 FY2025, posting EPS of $1.07 (in line with the analyst consensus of —). The next CARM earnings date is expected around September 1, 2026.
Each quarter, investors track CARM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CARM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CARM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CARM earnings · 4 questionsCarisma Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CARM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CARM historically reports after market close (AMC).
CARM earnings datewhen is CARM earningsCARM next earnings datewhen does CARM report earningsCARM earnings calendar
▸ Source: FMP · Carisma Therapeutics, Inc. SEC filings · US GAAP · Carisma Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026